CLA and Vitamin D on Protein Turnover (TM)

The Washington University

Status: Completed

Conditions: Protein

Treatments: Dietary Supplement: Conjugated linoleic acid; Dietary Supplement: Vitamin D; Other: Corn oil (placebo); Dietary Supplement: Conjugated linoleic acid and Vitamin D

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03115775

201702113

Details and patient eligibility

About

To conduct a randomized, double-blind, controlled clinical trial to determine the independent and combined effects of dietary conjugated linoleic acid (CLA) and vitamin D supplementation on anabolic signaling, the expression of growth regulatory factors, and muscle protein turnover in older adults.

Enrollment: 40 patients

Sex: All

Ages: 65 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI >/= 18.5 and </= 35.0
• Serum 25OH-VitD3 < 35 ng/ml

Exclusion criteria

• Diabetes
• COPD

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 4 patient groups, including a placebo group

Conjugated linoleic acid (Tonalin)

Active Comparator group

Description:

Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)

Treatment:

Dietary Supplement: Conjugated linoleic acid

Vitamin D

Active Comparator group

Description:

Vitamin D3 (2000 IU per day)

Treatment:

Dietary Supplement: Vitamin D

Conjugated linoleic acid and Vitamin D

Active Comparator group

Description:

Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day

Treatment:

Dietary Supplement: Conjugated linoleic acid and Vitamin D

Placebo

Placebo Comparator group

Description:

Corn oil (4000 mg per day)

Treatment:

Other: Corn oil (placebo)